Skip to main content
. 2025 May 6;10(5):105058. doi: 10.1016/j.esmoop.2025.105058

Figure 1.

Figure 1

Forest plot of overall survival by treatment arm in blood TMB subgroups. OS in bTMB subgroups for (A) T + D + CT versus CT and (B) D + CT versus CT. Data cut-off: 12 March 2021. bTMB, blood tumor mutational burden; CI, confidence interval; CT, chemotherapy; D, durvalumab; HR, hazard ratio; ITT, intention-to-treat; Mb, megabase; mut, mutations; OS, overall survival; PD-L1, programmed cell death-ligand 1; T, tremelimumab. aHRs and 95% CIs were estimated from an unstratified Cox proportional hazards model. ITT analyses were stratified by PD-L1 expression (TC ≥50% versus <50%), histology (squamous versus nonsquamous), and disease stage (IVA versus IVB).